Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions

Journal of Endovascular Therapy

Volumn 20, Issue 6, 2013, Pages 819-825

  Diehm, Nicolas ^a   Schneider, Henrique ^b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss Federation of Small and Medium Enterprises   (Switzerland)

Author keywords

Balloon angioplasty; Cost analysis; Diagnosis related group; Drug coated balloon; Drug eluting balloon; Femoropopliteal segment; Paclitaxel; Paclitaxel eluting balloon; Peripheral artery disease; Reimbursement; Restenosis; Target lesion revascularization

Indexed keywords

PACLITAXEL;

ARTERY OCCLUSION; ARTICLE; BUDGET; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING BALLOON ANGIOPLASTY; FEMORAL ARTERY; FEMOROPOPLITEAL ARTERIAL OBSTRUCTION; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTHESIS; INVESTMENT; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PHYSICIAN INCOME; POPLITEAL ARTERY; PRIORITY JOURNAL; REIMBURSEMENT;

ANGIOPLASTY, BALLOON; BUDGETS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; EQUIPMENT DESIGN; FEMORAL ARTERY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITAL COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LENGTH OF STAY; MODELS, ECONOMIC; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES;

EID: 84890098739     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/13-4416R.1     Document Type: Article

References (13)

1. Peach G, Griffin M, Jones KG, et al. Diagnosis and management of peripheral arterial disease. BMJ. 2012;345:e5208.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45:S5-S67.
3. Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. J Endovasc Ther. 2009;16 Suppl 1:I147-152.
4. Schillinger M, Haumer M, Schlerka G, et al. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. J Endovasc Ther. 2001;8:477-483.
5. Schillinger M, Exner M, Mlekusch W, et al. Restenosis after femoropopliteal PTA and elective stent implantation: predictive value of monocyte counts. J Endovasc Ther. 2003;10:557-565.
6. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
7. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
8. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840.
9. Wyler S. Inselspital Bern, internal controlling data. 2012.
10. SwissDRG System 2.0/2013. Available at: http://www.swissdrg.org/de/07- casemix-office/SwissDRG-System-20.asp?navid=27.
11. Staehelin E, Suter R, Siegwart N. Investitionsrechnung. Chur, Switzerland: Südostschweiz Print AG; 2007.
12. Breyer F, Zweifel P, Kifmann M. Gesundheitsökonomik. Vol 6. Heidelberg, Germany: Springer Gabler; 2012.
13. Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582-589.